An Israeli company specializing in rapid diagnostic solutions to the point-of-care (POC) and for self-testing has developed an innovative integrated platform and device for rapid diagnostic testing. Advantages include single step performance, high efficiency, easy-to-use, etc. The targeted partners are agents, representatives, distributors and manufacturers in the diagnostics field. The company is looking for commercial agency, distribution services and joint venture agreement.
The Israeli company was founded in 2004 with business focus of providing rapid diagnostic solutions to the point-of-care (POC) and for self-testing. The company develops, manufactures in an ISO13485:2016 approved facility, and markets a wide variety of rapid diagnostic tests (RDT), leading their adoption as first-line screening tool for physicians and patients. The company was the first to introduce rapid tests for strep A (group A streptococcus) diagnosis to Israeli pharmacies in 2004, allowing patients to purchase these tests over-the-counter (OTC) prior to visiting their primary care physician. This improved patients screening at the physician’s office, thus reducing antibiotics abuse, since a negative strep A result enables to avoid the administration of antibiotics to patients without strep A infection. An additional goal was to shift strep A screening from centralized labs to local point-of-care, improving HMO service when the centralized lab is inoperative (e.g., weekends) or overloaded. The company’s rapid diagnostic tests (RDT) cover most common diseases and healthcare fields, including: infectious disease, fertility, early markers of disease, urinalysis and urinary tract infection, drugs of abuse, etc. Customers in Israel include all major HMOs, major hospitals, military, police, pharmacies and pharma sale network, private clinics and medical centers. Of the estimated two million strep A tests annually performed in Israel, around 25% are RDT, thereby validating the chosen business model based on patients assuming responsibility for their own health first, followed by ENT (otolaryngology) and family physicians adoption and acceptance of strep A RDT as a reliable, first-line diagnostic standard.
The company is currently marketing its first of its kind, simple-to-use, innovative device, which provides an integrated platform for additional, single-step swab-based rapid diagnostic test development.
Applying this new platform to strep A diagnosis reduces performance complexity to a single step, eliminating the need for reagent mixing and dispensing, thereby making it simpler and faster to use. The offered test is popular and used at the physician’s office, allowing the healthcare professional to focus on the patient rather than dealing with cumbersome test performance steps and procedure.
The strep A diagnostic device is CE-marked and approved by the Israeli Ministry of Health, is currently distributed in Israel and Europe. It has replaced the previous 3-step RDT product, being sold directly to patients and physicians through Israeli pharmacies. The test is widely adopted by ENT and family physicians.
The company constantly expands its product line, by improving its existing products and adding new ones to its portfolio. They are seeking both distributors / agents / representatives for the current products (commercial agency, distribution services agreements) and original equipment manufacturers (OEM) of diagnostic products to co-develop additional applications for the core technologies under joint venture agreement.
- Type of partner sought: The developed platform is universal, by its nature, but offered RDT devices have their own indications for use, some of them requiring professional pharmacist assistance. This is defined by special regulations.
- Specific area of activity of the partner: -TYPE - industry, business, trade
-ACTIVITY – a) distributor / agent / representative (companies) – specializes in medical devices / diagnostics, has the corresponding connections with hospitals, pharmacies, clinics, HMO’s etc.
-ROLE - to find local customers
-ACTIVITY – b) original equipment manufacturers (OEM) of diagnostic products
-ROLE - to co-develop additional applications for the core technologies under joint venture agreement.
Innovative device, platform and proprietary swab for a single-step swab-based RDT integrating all components necessary to perform these tests, with the following advantages:
1) improving sample collection,
2) showing higher pathogen recovery efficacy
3) RDT simplification by minimizing the number of kit components,
4) reducing performance complexity to a one-step operation,
5) increasing RDT usability and adoption by untrained healthcare providers,
6) providing improved RDT accuracy,
7) test results available during in-patient visit,
8) minimal liquid waste disposal.
While RDTs for strep A infection diagnosis existed on the market for over 20 years, their wide-spread use by physicians and laboratories has been hampered by their relative operational complexity, requiring laborious and precise reagent dispensing and mixing for accurate disease diagnosis
Already on the market
Patent(s) applied for but not yet granted
Clasificado como: Manufactura Industrial \ Medicine and Health \ Industria
Seleccione una de las siguientes opciones para interesarse por esta oportunidad: